Earlier this year we covered a blueberry-sized capsule developed by researchers at MIT that would allow diabetics to take their insulin orally rather than by injection. That capsule contained microneedles to deliver the hormone through the stomach lining. Now, the same team has gone a step further, developing a new capsule that would survive a trip through the stomach and deliver its payload to the lining of the small intestine.
An impressive new study is suggesting a simple breath analysis can accurately predict whether lung cancer patients will positively respond to novel immunotherapy treatments. Unlike current methods, which involve studying tissue samples, the new “eNose” device can offer diagnostic advice in less than 60 seconds.
from the Blaze:
Hundreds of thousands of dollars worth of cocaine wash up on Florida beaches from Hurricane Dorian
Hurricane Dorian pushed hundreds of thousands of dollars worth of cocaine onto the beaches of Florida.
The first cocaine bricks, about 15 kilos worth in a red duffle bag, showed up over the weekend on Cocoa Beach. The cocaine was discovered by a beachgoer, who contacted the police. The find was reportedly worth roughly $300,000.
Alzheimer’s is a disease with a number of potential causes and therefore a number of potential targets for prevention. One of those centers on a protein call tau, which can gather in long tangles that kill off neurons in the brain. Scientists have developed what they describe as a vaccine to keep the brain clear of these dangerous clumps, and found that treating mice in this way helped stave off the kind of memory decline associated with the disease.
The venom of deadly animals mightn’t seem like a great place to look for life-saving medicines, but scientists are continually sifting through these toxins to discover compounds with huge potential. Now researchers at Stanford studying scorpion venom have identified a pair of compounds that were shown to kill off both staph and tuberculosis bacteria. And better yet, they were able to create synthetic versions in the lab.
Bacteria are quickly evolving resistances to antibiotics, to the extent that our best drugs might not work in the terrifyingly-near future. Scientists are hard at work developing new antibiotics, or finding ways to make existing ones more effective. Now, researchers from Thomas Jefferson University have found a new way to weaken bacterial defenses, slowing down the development of antibiotic resistance.
A shockwave reverberated through the Alzheimer’s research community today after pharmaceutical company Biogen announced it was discontinuing two massive final phase human trials into the previously promising Alzheimer’s drug aducanumab. The announcement is the latest in a long line of failed Alzheimer’s drugs targeting the popular amyloid protein hypothesis.